Impact of genetics on the clinical management of channelopathies

Journal of the American College of Cardiology

Volumn 62, Issue 3, 2013, Pages 169-180

  Schwartz, Peter J ^a,b,c,d,e   Ackerman, Michael J ^f,g   George, Alfred L ^h,i   Wilde, Arthur A M ^j,k  

^a UNIVERSITY OF PAVIA   (Italy)

^b FONDAZIONE IRCCS POLICLINICO SAN MATTEO   (Italy)

^c UNIVERSITY OF CAPE TOWN   (South Africa)

^d STELLENBOSCH UNIVERSITY   (South Africa)

^e KING SAUD UNIVERSITY   (Saudi Arabia)

^f MAYO CLINIC   (United States)

^g MAYO GRADUATE SCHOOL   (United States)

^h VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

ⁱ VANDERBILT UNIVERSITY   (United States)

^j ACADEMIC MEDICAL CENTER   (Netherlands)

^k KING ABDULAZIZ UNIVERSITY   (Saudi Arabia)

more..

Author keywords

channelopathies; gene specific management; genetic testing; heart rhythm disorder; sudden death

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; MEXILETINE;

ARTICLE; BRUGADA SYNDROME; CARDIAC CHANNELOPATHY; CATECHOLAMINERGIC POLYMORPHIC VENTRICULAR TACHYCARDIA; CAV3 GENE; CLINICAL FEATURE; DNA SEQUENCE; ELECTROCARDIOGRAPHY; EXERCISE TEST; GENE; GENE IDENTIFICATION; GENE MUTATION; GENETIC ASSOCIATION; GENETIC SCREENING; GENOTYPE; GENOTYPE PHENOTYPE CORRELATION; HEART REPOLARIZATION; HEART VENTRICLE FIBRILLATION; HETEROZYGOSITY; HOMOZYGOSITY; HUMAN; KCNH2 GENE; KCNQ1 GENE; LONG QT SYNDROME; LQT10 GENE; LQT12 GENE; LQT9 GENE; MISSENSE MUTATION; PATHOGENESIS; PRIORITY JOURNAL; SCN4B GENE; SCN5A GENE; SEX DIFFERENCE; SIGNAL TRANSDUCTION; SINGLE NUCLEOTIDE POLYMORPHISM; SNTA1 GENE; TORSADE DES POINTES;

EID: 84880078317     PISSN: 07351097     EISSN: 15583597     Source Type: Journal    
DOI: 10.1016/j.jacc.2013.04.044     Document Type: Review

References (107)

1. Q. Wang, J. Shen, and I. Splawski SCN5A mutations associated with an inherited cardiac arrhythmia, long QT syndrome Cell 80 1995 805 811
2. M.E. Curran, I. Splawski, and K.W. Timothy A molecular basis for cardiac arrhythmia: HERG mutations cause long QT syndrome Cell 80 1995 795 803
3. Q. Wang, M.E. Curran, and I. Splawski Positional cloning of a novel potassium channel gene: KvLQT1 mutations cause cardiac arrhythmias Nat Genet 12 1996 17 23
4. P.J. Schwartz, M. Periti, and A. Malliani The long Q-T syndrome Am Heart J 89 1975 378 390
5. P.J. Schwartz Idiopathic long QT syndrome: progress and questions Am Heart J 109 1985 399 411
6. P.J. Schwartz, L. Crotti, and R. Insolia Long QT syndrome: from genetics to management Circ Arrhythm Electrophysiol 5 2012 868 877
7. D.J. Tester, and M.J. Ackerman Genetic testing for potentially lethal, highly treatable inherited cardiomyopathies/channelopathies in clinical practice Circulation 123 2011 1021 1037
8. P.J. Schwartz, and M.J. Ackerman The long QT syndrome: a transatlantic clinical approach to diagnosis and therapy Eur Heart J 2013 Mar 18 [E-pub ahead of print] http://dx.doi.org/10.1093/eurheartj/eht089
9. D.J. Tester, and M.J. Ackerman Postmortem long QT syndrome genetic testing for sudden unexplained death in the young J Am Coll Cardiol 49 2007 240 246
10. P.J. Schwartz, M. Stramba-Badiale, and L. Crotti Prevalence of the congenital long-QT syndrome Circulation 120 2009 1761 1767
11. P.J. Schwartz, C. Spazzolini, and L. Crotti The Jervell and Lange-Nielsen Syndrome. Natural history, molecular basis, and clinical outcome Circulation 113 2006 783 790
12. M. Arnestad, L. Crotti, and T.O. Rognum Prevalence of long QT syndrome gene variants in sudden infant death syndrome Circulation 115 2007 361 367
13. L. Crotti, D.J. Tester, and W.M. White Long QT syndrome associated mutations in intrauterine fetal death JAMA 309 2013 1473 1482
14. G. Malfatto, G. Beria, S. Sala, O. Bonazzi, and P.J. Schwartz Quantitative analysis of T wave abnormalities and their prognostic implications in the idiopathic long QT syndrome J Am Coll Cardiol 23 1994 296 301
15. P.J. Schwartz, and A. Malliani Electrical alternation of the T wave. Clinical and experimental evidence of its relationship with the sympathetic nervous system and with the long QT syndrome Am Heart J 89 1975 45 50
16. P.J. Schwartz, A.J. Moss, G.M. Vincent, and R.S. Crampton Diagnostic criteria for the long QT syndrome: an update Circulation 88 1993 782 784
17. P. Chockalingam, G. Girardengo, and L. Crotti Not all beta-blockers are equal in the management of long QT syndrome types 1 and 2 J Am Coll Cardiol 60 2012 2092 2099
18. P.J. Schwartz Cutting nerves and saving lives Heart Rhythm 6 2009 760 763
19. C.A. Collura, J.N. Johnson, C. Moir, and M.J. Ackerman Left cardiac sympathetic denervation for the treatment of long QT syndrome and catecholaminergic polymorphic ventricular tachycardia using video-assisted thoracic surgery Heart Rhythm 6 2009 752 759
20. P.J. Schwartz, C. Spazzolini, and S.G. Priori Who are the long-QT syndrome patients who receive an implantable cardioverter defibrillator and what happens to them? Data from the European long-QT syndrome implantable cardioverter-defibrillator (LQTS ICD) Registry Circulation 122 2010 1272 1282
21. A. Barsheshet, I. Goldenberg, and J. O-Uchi Mutations in cytoplasmic loops of the KCNQ1 channel and the risk of life-threatening events: implications for mutation-specific response to β-blocker therapy in type 1 long-QT syndrome Circulation 125 2012 1988 1996
22. J. Heijman, R.L. Spätjens, and J. Heijman Dominant-negative control of cAMP-dependent IKs upregulation in human long-QT syndrome type 1 Circ Res 110 2012 211 219
23. C.L. Anderson, B.P. Delisle, and B.D. Anson Most LQT2 mutations reduce Kv11.1 (hERG) current by a class 2 (trafficking-deficient) mechanism Circulation 113 2006 365 373
24. P.B. Bennett, K. Yazawa, N. Makita, and A.L. George Jr. Molecular mechanism for an inherited cardiac arrhythmia Nature 376 1995 683 685
25. M. Vatta, M.J. Ackerman, and B. Ye Mutant caveolin-3 induces persistent late sodium current and is associated with long QT syndrome Circulation 114 2006 2104 2112
26. A. Medeiros-Domingo, T. Kaku, and D.J. Tester Sodium channel β4 subunit (SCN4β) mutation causes congenital long QT syndrome Circulation 116 2007 134 142
27. K. Ueda, C. Valdivia, and A. Medeiros-Domingo Syntrophin mutation associated with long QT syndrome through activation of the nNOS-SCN5A macromolecular complex Proc Natl Acad Sci U S A 105 2008 9355 9360
28. L. Crotti, C.N. Johnson, and E. Graf Calmodulin mutations associated with recurrent cardiac arrest in infants Circulation 127 2013 1009 1017
29. L.S. Maier, D.M. Bers, and J.H. Brown Calmodulin and Ca2+/calmodulin kinases in the heart - physiology and pathophysiology Cardiovasc Res 73 2007 629 630
30. B.A. Alseikhan, C.D. DeMaria, H.M. Colecraft, and D.T. Yue Engineered calmodulins reveal the unexpected eminence of Ca2+ channel inactivation in controlling heart excitation Proc Natl Acad Sci U S A 99 2002 17185 17190
31. P.J. Schwartz, S.G. Priori, and C. Spazzolini Genotype-phenotype correlation in the long-QT syndrome: gene-specific triggers for life-threatening arrhythmias Circulation 103 2001 89 95
32. S.G. Priori, P.J. Schwartz, and C. Napolitano Risk stratification in the long-QT syndrome N Engl J Med 348 2003 1866 1874
33. P.J. Schwartz The long QT syndrome H.E. Kulbertus, H.J.J. Wellens, Sudden Death 1980 M. Nijhoff Publishers The Hague 358 378
34. S.G. Priori, C. Napolitano, and P.J. Schwartz Low penetrance in the long-QT syndrome: clinical impact Circulation 99 1999 529 533
35. A.J. Moss, W. Zareba, E.S. Kaufman, and E. Gartman Increased risk of arrhythmic events in long-QT syndrome with mutations in the pore region of the human ether-a-go-go-related gene potassium channel Circulation 105 2002 794 799
36. A.J. Moss, W. Shimizu, and A.A. Wilde Clinical aspects of type-1 long-QT syndrome by location, coding type, and biophysical function of mutations involving the KCNQ1 gene Circulation 115 2007 2481 2489
37. P.A. Brink, L. Crotti, and V. Corfield Phenotypic variability and unusual clinical severity of congenital long QT syndrome in a founder population Circulation 112 2005 2602 2610
38. L. Crotti, C. Spazzolini, and P.J. Schwartz The common long QT syndrome mutation KCNQ1/A341V causes unusually severe clinical manifestations in patients with different ethnic backgrounds: toward a mutation-specific risk stratification Circulation 116 2007 2366 2375
39. S.G. Priori, C. Napolitano, and P.J. Schwartz Association of long QT syndrome loci and cardiac events among patients treated with ß-blockers JAMA 292 2004 1341 1344
40. G.M. Vincent, P.J. Schwartz, and I. Denjoy High efficacy of beta-blockers in long-QT syndrome type 1: contribution of noncompliance and QT-prolonging drugs to the occurrence of beta-blocker treatment "failures" Circulation 119 2009 215 221
41. P.J. Schwartz, C. Spazzolini, and L. Crotti All LQT3 patients need an ICD. True or false? Heart Rhythm 6 2009 113 120
42. A.A. Wilde, E.S. Kaufman, and W. Shimizu Sodium channel mutations, risk of cardiac events, and efficacy of beta-blocker therapy in type 3 long QT syndrome (abstr) Heart Rhythm 9 May Suppl 2012 S321
43. P.J. Schwartz, S.G. Priori, and E.H. Locati Long QT syndrome patients with mutations of the SCN5A and HERG genes have differential responses to Na+ channel blockade and to increases in heart rate. Implications for gene-specific therapy Circulation 92 1995 3381 3386
44. R. Dumaine, Q. Wang, and M.T. Keating Multiple mechanisms of Na+ channel-linked long-QT syndrome Circ Res 78 1996 916 924
45. B. Lown Management of patients at high risk of sudden death Am Heart J 103 4 Pt 2 1982 689 697
46. A.J. Moss, W. Zareba, K.Q. Schwarz, S. Rosero, S. McNitt, and J.L. Robinson Ranolazine shortens repolarization in patients with sustained inward sodium current due to type-3 long-QT syndrome J Cardiovasc Electrophysiol 19 2008 1289 1293
47. D.W. Wang, L. Crotti, and W. Shimizu Malignant perinatal variant of long QT syndrome caused by a profoundly dysfunctional cardiac sodium channel Circ Arrhythm Electrophysiol 1 2008 370 378
48. P.J. Schwartz Cascades or waterfalls, the cataracts of genetic screening are being opened on clinical cardiology J Am Coll Cardiol 55 2010 2577 2579
49. N. Hofman, H.L. Tan, M. Alders, I.M. van Langen, and A.A. Wilde Active cascade screening in primary inherited arrhythmia syndromes: does it lead to prophylactic treatment? J Am Coll Cardiol 55 2010 2570 2576
50. P. Coumel, J. Fidelle, and V. Lucet Catecholaminergic-induced severe ventricular arrhythmias with Adams-Stokes syndrome in children: report of four cases Br Heart J 40 1978 28 37
51. A. Leenhardt, V. Lucet, and I. Denjoy Catecholaminergic polymorphic ventricular tachycardia in children. A 7-year follow-up of 21 patients Circulation 91 1995 1512 1519
52. M. Hayashi, I. Denjoy, and F. Extramiana Incidence and risk factors of arrhythmic events in catecholaminergic polymorphic ventricular tachycardia Circulation 119 2009 2426 2434
53. J.M. Horner, and M.J. Ackerman Ventricular ectopy during treadmill exercise stress testing in the evaluation of long QT syndrome Heart Rhythm 5 2008 1690 1694
54. S.G. Priori, C. Napolitano, and M. Memmi Clinical and molecular characterization of patients with catecholaminergic polymorphic ventricular tachycardia Circulation 106 2002 69 74
55. D.J. Tester, L.J. Kopplin, M.L. Will, and M.J. Ackerman Spectrum and prevalence of cardiac ryanodine receptor (RyR2) mutations in a cohort of unrelated patients referred explicitly for long QT syndrome genetic testing Heart Rhythm 2 2005 1099 1105
56. S.G. Priori, C. Napolitano, and N. Tiso Mutations in the cardiac ryanodine receptor gene (hRyR2) underlie catecholaminergic polymorphic ventricular tachycardia Circulation 103 2001 196 200
57. A. Medeiros-Domingo, Z.A. Bhuiyan, and D.J. Tester The RYR2-encoded ryanodine receptor/calcium release channel in patients diagnosed previously with either catecholaminergic polymorphic ventricular tachycardia or genotype negative, exercise-induced long QT syndrome: a comprehensive open reading frame mutational analysis J Am Coll Cardiol 54 2009 2065 2074
58. M. Eldar, E. Pras, and H. Lahat A missense mutation in the CASQ2 gene is associated with autosomal-recessive catecholamine-induced polymorphic ventricular tachycardia Trends Cardiovasc Med 13 2003 148 151
59. N. Roux-Buisson, M. Cacheux, and A. Fourest-Lieuvin Absence of triadin, a protein of the calcium release complex, is responsible for cardiac arrhythmia with sudden death in humans Hum Mol Genet 21 2012 2759 2767
60. M. Nyegaard, M.T. Overgaard, and M.T. Søndergaard Mutations in calmodulin cause ventricular tachycardia and sudden cardiac death Am J Hum Genet 91 2012 703 712
61. M.J. Ackerman, S.G. Priori, and S. Willems Heart Rhythm Society; European Heart Rhythm Association HRS/EHRS expert consensus statement on the state of genetic testing for the channelopathies and cardiomyopathies: this document was developed as a partnership between the Heart Rhythm Society (HRS) and the European Heart Rhythm Association Heart Rhythm 8 2011 1308 1339
62. D.J. Tester, P. Arya, and M. Will Genotypic heterogeneity and phenotypic mimicry among unrelated patients referred for catecholaminergic polymorphic ventricular tachycardia genetic testing Heart Rhythm 3 2006 800 805
63. D.J. Tester, and M.J. Ackerman Genetic testing for potentially lethal, highly treatable inherited cardiomyopathies/channelopathies in clinical practice Circulation 123 2011 1021 1037
64. C. van der Werf, I. Nederend, and N. Hofman Familial evaluation in catecholaminergic polymorphic ventricular tachycardia: disease penetrance and expression in cardiac ryanodine receptor mutation-carrying relatives Circ Arrhythm Electrophysiol 5 2012 748 756
65. A.A. Wilde, Z.A. Bhuiyan, and L. Crotti Left cardiac sympathetic denervation for catecholaminergic polymorphic ventricular tachycardia N Engl J Med 358 2008 2024 2029
66. M.A. Coleman, J.M. Bos, and J.N. Johnson Videoscopic left cardiac sympathetic denervation for patients with recurrent ventricular fibrillation/malignant ventricular arrhythmia syndromes besides congenital long QT syndrome Circ Arrhyth Electrophysiol 5 2012 782 788
67. H. Watanabe, N. Chopra, and D. Laver Flecainide prevents catecholaminergic polymorphic ventricular tachycardia in mice and humans Nat Med 15 2009 380 383
68. C. van der Werf, P.J. Kannankeril, and F. Sacher Flecainide therapy reduces exercise-induced ventricular arrhythmias in patients with catecholaminergic polymorphic ventricular tachycardia J Am Coll Cardiol 57 2011 2244 2254
69. U. Mohamed, M.H. Gollob, R.M. Gow, and A.D. Krahn Sudden cardiac death despite an implantable cardioverter-defibrillator in a young female with catecholaminergic ventricular tachycardia Heart Rhythm 3 2006 1486 1489
70. S. Pizzale, M.H. Gollob, R. Gow, and D.H. Birnie Sudden death in a young man with catecholaminergic polymorphic ventricular tachycardia and paroxysmal atrial fibrillation J Cardiovasc Electrophysiol 19 2008 1319 1321
71. R. Bokenkamp, A.A. Wilde, M.J. Schalij, and N.A. Blom Flecainide for recurrent malignant ventricular arrhythmias in two siblings with Andersen-Tawil syndrome Heart Rhythm 4 2007 508 511
72. D.J. Tester, A. Medeiros-Domingo, M.L. Will, C.M. Haglund, and M.J. Ackerman Cardiac channel molecular autopsy: insights from 173 consecutive cases of autopsy-negative sudden unexplained death referred for postmortem genetic testing Mayo Clinic Proc 87 2012 524 539
73. P. Brugada, and J. Brugada Right bundle branch block, persistent ST segment elevation and sudden cardiac death: a distinct clinical and electrocardiographic syndrome. A multicenter report J Am Coll Cardiol 20 1992 1391 1396
74. A.A. Wilde, C. Antzelevitch, and M. Borggrefe Proposed diagnostic criteria for the Brugada syndrome: consensus report Circulation 106 2002 2514 2519
75. A.A.M. Wilde, P.G. Postema, and J.M. Diego The pathophysiological mechanism underlying Brugada syndrome. Depolarization versus repolarization. Point/counterpoint J Mol Cell Cardiol 49 2010 543 553
76. Y. Mizusawa, and A.A. Wilde Brugada syndrome Circ Arrhythm Electrophysiol 5 2012 606 616
77. L. Crotti, C.A. Marcou, and D.J. Tester Spectrum and prevalence of mutations involving BrS1- through BrS12-susceptibility genes in a cohort of unrelated patients referred for Brugada syndrome genetic testing: implications for genetic testing J Am Coll Cardiol 60 2012 1410 1418
78. J.D. Kapplinger, D.J. Tester, and M. Alders An international compendium of mutations in the SCN5A-encoded cardiac sodium channel in patients referred for Brugada syndrome genetic testing Heart Rhythm 7 2010 33 46
79. V. Probst, A.A. Wilde, and J. Barc SCN5A mutations and the role of genetic background in the pathophysiology of Brugada syndrome Circ Cardiovasc Genet 2 2009 552 557
80. J.P.P. Smits, L. Eckardt, and V. Probst Genotype-phenotype relationship in Brugada syndrome; electrocardiographic features differentiate SCN5A-related patients from non SCN5A related patients J Am Coll Cardiol 40 2002 350 356
81. A.K. Gehi, T.D. Duong, L.D. Metz, J.A. Gomes, and D. Mehta Risk stratification of individuals with the Brugada electrocardiogram: a meta-analysis J Cardiovasc Electrophysiol 17 2006 577 583
82. P.G. Meregalli, H.L. Tan, and V. Probst Type of SCN5A mutation determines clinical severity and degree of conduction slowing in loss-of-function sodium channelopathies Heart Rhythm 6 2009 341 348
83. C. Antzelevitch, G.D. Pollevick, and J.M. Cordeiro Loss-of-function mutations in the cardiac calcium channel underlie a new clinical entity characterized by ST-segment elevation, short QT intervals, and sudden cardiac death Circulation 115 2007 442 449
84. P.G. Postema, C. Wolpert, and A.S. Amin Drugs and Brugada syndrome patients: review of the literature, recommendations, and an up-to-date website (www.brugadadrugs.org) Heart Rhythm 6 2009 1335 1341
85. C.C. Chang, S. Acharfi, and M.H. Wu A novel SCN5A mutation manifests as a malignant form of long QT syndrome with perinatal onset of tachycardia/ bradycardia Cardiovasc Res 64 2004 268 278
86. J.R. Bankston, M. Yue, and W. Chung A novel and lethal de novo LQT-3 mutation in a newborn with distinct molecular pharmacology and therapeutic response PLoS One 2 2007 e1258
87. D.J. Tester, M.L. Will, C.M. Haglund, and M.J. Ackerman Compendium of cardiac channel mutations in 541 consecutive unrelated patients referred for long QT syndrome genetic testing Heart Rhythm 2 2005 507 517
88. M.K. Schwartz Genetic testing and the clinical laboratory improvement amendments of 1988: present and future Clin Chem 45 1999 739 745
89. M.J. Ackerman, I. Splawski, and J.C. Makielski Spectrum and prevalence of cardiac sodium channel variants among black, white, Asian, and Hispanic individuals: implications for arrhythmogenic susceptibility and Brugada/long QT syndrome genetic testing Heart Rhythm 1 2004 600 607
90. J.D. Kapplinger, D.J. Tester, and B.A. Salisbury Spectrum and prevalence of mutations from the first 2,500 consecutive unrelated patients referred for the FAMILION long QT syndrome genetic test Heart Rhythm 6 2009 1297 1303
91. S. Kapa, D.J. Tester, and B.A. Salisbury Genetic testing for long-QT syndrome: distinguishing pathogenic mutations from benign variants Circulation 120 2009 1752 1760
92. L. Crotti, M.A. Lewandowska, and P.J. Schwartz A KCNH2 branch point mutation causing aberrant splicing contributes to an explanation of genotype-negative long QT syndrome Heart Rhythm 6 2009 212 218
93. D.J. Tester, A.J. Benton, L. Train, B. Deal, L.M. Baudhuin, and M.J. Ackerman Prevalence and spectrum of large deletions or duplications in the major long QT syndrome-susceptibility genes and implications for long QT syndrome genetic testing Am J Cardiol 106 2010 1124 1128
94. C.A. Eddy, J.M. MacCormick, and S.K. Chung Identification of large gene deletions and duplications in KCNQ1 and KCNH2 in patients with long QT syndrome Heart Rhythm 5 2008 1275 1281
95. T.T. Koopmann, M. Alders, and R.J. Jongbloed Long QT syndrome caused by a large duplication in the KCNH2 (HERG) gene undetectable by current polymerase chain reaction-based exon-scanning methodologies Heart Rhythm 3 2006 52 55
96. M.M. Medlock, D.J. Tester, M.L. Will, J.M. Bos, and M.J. Ackerman Repeat long QT syndrome genetic testing of phenotype-positive cases: prevalence and etiology of detection misses Heart Rhythm 9 2012 1977 1982
97. P.A. Brink, L. Crotti, and V. Corfield Phenotypic variability and unusual clinical severity of congenital long-QT syndrome in a founder population Circulation 112 2005 2602 2610
98. P.J. Schwartz, S.G. Priori, and C. Napolitano How really rare are rare diseases? The intriguing case of independent compound mutations in the long QT syndrome J Cardiovasc Electrophysiol 14 2003 1120 1121
99. P. Westenskow, I. Splawski, K.W. Timothy, M.T. Keating, and M.C. Sanguinetti Compound mutations: a common cause of severe long-QT syndrome Circulation 109 2004 1834 1841
100. P.J. Schwartz, E. Vanoli, and L. Crotti Neural control of heart rate is an arrhythmia risk modifier in long QT syndrome J Am Coll Cardiol 51 2008 920 929
101. H. Fodstad, H. Swan, and P. Laitinen Four potassium channel mutations account for 73% of the genetic spectrum underlying long-QT syndrome (LQTS) and provide evidence for a strong founder effect in Finland Ann Med 36 Suppl 1 2004 53 63
102. L. Crotti, M.C. Monti, and R. Insolia NOS1AP is a genetic modifier of the long-QT syndrome Circulation 120 2009 1657 1663
103. M. Tomas, C. Napolitano, and L. De Giuli Polymorphisms in the NOS1AP gene modulate QT interval duration and risk of arrhythmias in the long QT syndrome J Am Coll Cardiol 55 2010 2745 2752
104. A.S. Amin, J.R. Giudicessi, and A.J. Tijsen Variants in the 3' untranslated region of the KCNQ1-encoded Kv7.1 potassium channel modify disease severity in patients with type 1 long QT syndrome in an allele-specific manner Eur Heart J 33 2012 714 723
105. Y. Nishio, T. Makiyama, and H. Itoh D85N, a KCNE1 polymorphism, is a disease-causing gene variant in long QT syndrome J Am Coll Cardiol 54 2009 812 819
106. S. Kääb, D.C. Crawford, and M.F. Sinner A large candidate gene survey identifies the KCNE1 D85N polymorphism as a possible modulator of drug-induced torsades de pointes Circ Cardiovasc Genet 5 2012 91 99
107. L. Refsgaard, A.G. Holst, G. Sadjadieh, S. Haunso, J.B. Nielsen, and M.S. Olesen High prevalence of genetic variants previously associated with LQT syndrome in new exome data Eur J Hum Genet 20 2012 905 908